Skip to main content

ForFarmers results for the first half of 2026: Continued strong results and further market share growth

Lochem, 6th August 2026 ForFarmers results for the first half of 2026Continued strong results and further market share growth Pieter Wolleswinkel, CEO ForFarmers: “We successfully sustained the strong results achieved in the first quarter throughout the second quarter. Volume development remained positive, demonstrating that we have further strengthened our market positions. The dedication and commitment of our people in serving our customers have played a major role in this achievement. Underlying profit increased significantly once again compared with the first half of last year, rising by almost 60%. This growth was primarily driven by strong performances in the Netherlands, Germany and Poland. Results in the UK remained satisfactory. In the Netherlands in particular, we continue to invest in and focus on innovation at the farm level...

Continue reading

Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update

Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business UpdateStrategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet negotiations for a potential licensing agreement Gained further insight into varoglutamstat’s unique mechanism of action and therapeutic potential in kidney disease Financial guidance maintained: Vivoryon expects cash and cash equivalents to be sufficient for funding operations into Q4 2026 Management to host a conference call today at 3:00 pm CEST (9:00 am EDT)Halle (Saale) / Munich, Germany, August 6, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney...

Continue reading

Predictive Discovery Limited: General Meeting Webinar Invite

QUEBEC CITY, Aug. 06, 2026 (GLOBE NEWSWIRE) — Predictive Discovery Limited (ASX:PDI, TSX:PDI) (“PDI” or the “Company”) advises shareholders that registration is now open to attend the webinar of the Company’s General Meeting to be held at 3:00pm (Australian Western Standard Time) on Friday, 21 August 2026 (“Meeting”). Shareholders and interested parties who wish to attend the Meeting via the webinar are required to register using the link below.Details for the MeetingDate:  Australia: Friday, 21 August 2026 at 3:00pm (AWST) / 5:00pm (AEST)Canada: Friday, 21 August 2026 at 3:00am (EDT, Canada)Venue:  Grant Thornton Australia, Central Park, Level 43, 152 -158 St Georges Terrace, Perth Western Australia, 6000Registration link: Click Here to Register   Registered attendees will be able to listen and ask questions...

Continue reading

EfTEN United Property Fund unaudited financial results for 2nd quarter and I half-year of 2026

In the second quarter of 2026, EfTEN United Property Fund earned a net profit of EUR 248 thousand (Q2 2025: EUR 976 thousand). The decrease in profit is primarily related to the regular valuation of property investments carried out at the end of the half-year, as well as to the fund’s investment in the development company Invego Uus-Järveküla OÜ, where the majority of the terraced houses’ sales and the recorded profit took place in the first half of last year. Despite the decrease in profit, EfTEN United Property Fund received record distributions from its underlying funds at the beginning of 2026. In June 2026, the fund made its first distribution of the year to investors in the amount of EUR 1,060 thousand, or 42.676 cents per unit. The distribution was based on dividends and income received from all underlying funds, as well as...

Continue reading

Mowi ASA (OSE:MOWI): Presentation of Q2 2026 results 18 August 2026 at 08:00 (CET)

Mowi ASA hereby invites you to the presentation of the results for the second quarter 2026 at The Salmon, Strandpromenaden 11, 0252 Oslo, Norway. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/ A recording of the webcast will be made available on our website immediately afterwards. Please note that the quarterly report and presentation will be published at 06:30 (CET). This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue reading

GCL Announces Plan to Propose Adjournment of Extraordinary General Meeting to December 1, 2026 at Its August 7, 2026 Meeting

SINGAPORE, Aug. 06, 2026 (GLOBE NEWSWIRE) — GCL Global Holdings Ltd. (Nasdaq: GCL) (“GCL” or the “Company”), a leading provider of games and entertainment, today announced that it plans to propose to shareholders at the Extraordinary General Meeting of Shareholders to be held on August 7, 2026, at 9 am, Singapore time at 29 Tai Seng Ave., #02-01, Singapore, that they consider and approve an adjournment of the meeting to December 1, 2026, at the same time and place as originally convened. Reason for the Proposed Adjournment: The Company continues to assess its compliance with applicable Nasdaq listing requirements and has concluded that the proposed share consolidation may not be necessary at this time. The planned adjournment proposal seeks to allow the Company additional time to evaluate the available options and determine the...

Continue reading

McEwen Q2 Results: Net Income of $9.6M ($0.16 per Share), Compared with $3.0M ($0.06 per Share) in Q2 2025; Exploration Results Driving Resource Growth Across All Sites; New Stock Mine in Timmins Nearing Production, with Mine Life Extended

(See Glossary for Defined Terms) TORONTO, Aug. 05, 2026 (GLOBE NEWSWIRE) — McEwen Inc. (NYSE/TSX: MUX) (“McEwen” or the “Company”) today announced its second quarter financial results for the period ended June 30, 2026 (Q2). In addition, the Company is providing an update on its development projects that are forecasted to increase annual production to 250,000 – 300,000 GEOs by 2030 and new exploration results that have intersected very encouraging high grades at the Grey Fox Project, part of the Fox Complex (97.7 gpt gold over 4.4 meters, 64.8 gpt gold over 3.3 meters and 32.5 gpt gold over 5.2 meters) and Tartan Mine Project (17.8 gpt gold over 15.9 meters and 29.1 gpt gold over 10.0 meters). During Q2 the exploration teams at Grey Fox and Tartan have each made new discoveries near existing underground infrastructure, demonstrating...

Continue reading

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE.” The offering is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Braveheart Bio. Braveheart Bio has granted the underwriters a 30-day option to purchase up to an additional 3,187,500 shares of its common stock at the initial...

Continue reading

Fortuna Reports Results for the Second Quarter 2026

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated) Fortuna Delivers Strong Q2 Results; Positioned To Deliver Our Next Phase of Growth VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) (“Fortuna” or the “Company”) today reported its financial and operating results for the second quarter of 2026.(Results from the Company’s San Jose and Yaramoko assets have been excluded from the 2025 comparative figures as they were disposed of during the second quarter of 2025.) Jorge Ganoza, President and CEO of Fortuna, commented, “Fortuna delivered another strong quarter of production, generating $85.7 million of free cash flow from ongoing operations and $200.8 million in adjusted EBITDA, with a robust EBITDA margin of 63%. The second quarter...

Continue reading

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibody, in combination with bevacizumab for the treatment of first-line hepatocellular carcinoma (HCC) has successfully completed the safety run-in phase assessment following expert review and has advanced into the expansion phase. The study is led by Professor Zhou Jian, President of Zhongshan Hospital, Fudan University, and Academician of the Chinese Academy of Sciences. Preliminary clinical data demonstrated that Opamtistomig in combination with bevacizumab has shown encouraging anti-tumor activity and a favorable safety profile in patients with HCC, supporting further...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.